NIMA-related kinase 2 regulates hepatocellular carcinoma cell growth and proliferation
Xiao-Bo Lai1,2, Yu-Qiang Nie1,2, Hong-Li Huang1,2
1Department of Gastroenterology and Hepatology, The First Municipal People's Hospital of Guangzhou, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China.
Abstract:
NIMA-related kinase 2 (Nek2) is often upregulated in human cancer and is important in regulating the cell cycle and gene expression, and maintaining centrosomal structure and function. The present study aimed to investigate the expression pattern, clinical significance, and biological function of Nek2 in hepatocellular carcinoma (HCC). mRNA and protein levels of Nek2 were examined in HCC and corresponding normal liver tissues. The MTT and soft agar colony formation assays, and flow cytometry were employed to assess the roles of Nek2 in cell proliferation and growth. In addition, western blot analysis was performed to assess the expression of cell cycle- and proliferation-related proteins. The results revealed that Nek2 was upregulated in HCC tissues and cell lines. The clinical significance of Nek2 expression was also analyzed. Inhibiting Nek2 expression by siRNA suppressed cell proliferation, growth, and colony formation in hepatocellular carcinoma cell line HepG2 cells, induced cell cycle arrest in the G2/M phase by retarding the S-phase, and promoted apoptosis. Furthermore, Nek2 depletion downregulated β-catenin expression in HepG2 cells and diminished expression of Myc proto-oncogene protein (c-Myc), cyclins D1, B1, and E and cyclin-dependent kinase 1, whilst increasing protein levels of p27. This demonstrates that overexpression of Nek2 is associated with the malignant evolution of HCC. Targeting Nek2 may inhibit HCC cell growth and proliferation through the regulation of β-catenin by the Wnt/β-catenin pathway and therefore may be developed as a novel therapeutic strategy to treat HCC.
Insights
NIMA-related kinase 2 (Nek2) is overexpressed in hepatocellular carcinoma (HCC), driving cancer growth and proliferation. Inhibiting Nek2 shows promise as a novel therapeutic strategy for HCC by impacting cell cycle and apoptosis.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- NIMA-related kinase 2 (Nek2) is frequently upregulated in human cancers.
- Nek2 plays critical roles in cell cycle regulation, gene expression, and centrosome function.
- Hepatocellular carcinoma (HCC) is a major global health concern with a need for novel therapeutic targets.
Purpose of the Study:
- To investigate the expression pattern, clinical significance, and biological function of Nek2 in HCC.
- To determine the role of Nek2 in HCC cell proliferation, cell cycle progression, and apoptosis.
- To explore the molecular mechanisms underlying Nek2's function in HCC, including its effect on key signaling pathways.
Main Methods:
- Analysis of Nek2 mRNA and protein levels in HCC and normal liver tissues.
- In vitro assays including MTT, soft agar colony formation, and flow cytometry to assess cell proliferation and growth.
- Western blot analysis to evaluate the expression of cell cycle-related proteins (e.g., c-Myc, cyclins, p27) and β-catenin.
- RNA interference (siRNA) to inhibit Nek2 expression in HepG2 HCC cells.
Main Results:
- Nek2 expression was significantly upregulated in HCC tissues and cell lines compared to normal controls.
- Inhibition of Nek2 by siRNA suppressed HCC cell proliferation, colony formation, and induced apoptosis.
- Nek2 depletion led to G2/M cell cycle arrest, downregulation of β-catenin, c-Myc, cyclins D1, B1, E, and cyclin-dependent kinase 1, and upregulation of p27.
- Overexpression of Nek2 correlates with the malignant progression of HCC.
Conclusions:
- Nek2 is a key driver of HCC progression and is associated with poor clinical outcomes.
- Targeting Nek2 can inhibit HCC cell growth and proliferation.
- Nek2 may exert its oncogenic effects by regulating the Wnt/β-catenin pathway and downstream targets like c-Myc and cyclins.
- Nek2 represents a potential novel therapeutic target for hepatocellular carcinoma treatment.
More Related Videos
08:50In Vitro Cultivation Techniques for Modeling Liver Organogenesis, Building Assembloids, and Designing Synthetic Tissues using Human Cell Lines
Published on: April 18, 2025
10:35Generation of Subcutaneous and Intrahepatic Human Hepatocellular Carcinoma Xenografts in Immunodeficient Mice
Published on: September 25, 2013
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
MAPK Signaling Cascades
Abnormal Proliferation
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
